Penumbra (PEN) Total Non-Current Liabilities (2014 - 2026)

Penumbra's (PEN) quarterly Total Non-Current Liabilities came in at $411.4 million in Q1 2026, up 12.87% year-on-year from $364.5 million in Q1 2025, and up 6.41% on a QoQ basis from $386.6 million in Q4 2025.

Penumbra (PEN) Total Non-Current Liabilities (2014 - 2026) Analysis & Trends

Penumbra (PEN) has 13 years of Total Non-Current Liabilities data on file, last reported at $411.4 million in Q1 2026.

  • On a quarterly basis, Total Non-Current Liabilities rose 12.87% year-over-year to $411.4 million in Q1 2026; TTM through Mar 2026 was $411.4 million, a 12.87% increase from a year earlier, with the FY2025 full-year figure at $386.6 million, up 5.3% from the prior year.
  • Total Non-Current Liabilities for Q1 2026 stood at $411.4 million, up from $386.6 million in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for PEN reached as high as $411.4 million in Q1 2026 and fell as low as $338.7 million in Q1 2022.
  • Historically, Total Non-Current Liabilities has averaged $366.8 million across 5 years, with a median of $365.7 million in 2024.
  • Across the five-year window, Total Non-Current Liabilities soared 85.68% in 2022 and dropped 1.61% in 2025, its largest moves.
  • Year by year, Total Non-Current Liabilities stood at $368.8 million in 2022, then rose by 0.9% to $372.1 million in 2023, then fell by 1.32% to $367.1 million in 2024, then gained by 5.3% to $386.6 million in 2025, then climbed by 6.41% to $411.4 million in 2026.
  • Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $411.4 million in Q1 2026, $386.6 million in Q4 2025, and $371.1 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Abbott Laboratories 201.40 Bn 194.75 Bn 6.27 Bn -
2 Stryker 122.29 Bn 119.41 Bn 3.81 Bn 20.94 Bn
3 Medtronic 105.01 Bn 96.40 Bn 6.41 Bn 41.44 Bn
4 Boston Scientific 64.81 Bn 63.59 Bn 3.61 Bn 41.88 Bn
5 Edwards Lifesciences 55.28 Bn 51.60 Bn 1.29 Bn 2.64 Bn
6 Dexcom 29.06 Bn 27.94 Bn 750.30 Mn 3.53 Bn
7 Koninklijke Philips 29.02 Bn 25.93 Bn 2.07 Bn 9.85 Bn
8 GE HealthCare Technologies 28.27 Bn 26.20 Bn 1.98 Bn 24.21 Bn
9 Smith & Nephew 25.80 Bn 25.22 Bn - 3.57 Bn
10 Penumbra 12.48 Bn 11.87 Bn 253.41 Mn 411.38 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 411.38 Mn
Dec 31, 2025 386.60 Mn
Sep 30, 2025 371.14 Mn
Jun 30, 2025 363.04 Mn
Mar 31, 2025 364.48 Mn
Dec 31, 2024 367.14 Mn
Sep 30, 2024 365.39 Mn
Jun 30, 2024 365.71 Mn
Mar 31, 2024 370.44 Mn
Dec 31, 2023 372.05 Mn
Sep 30, 2023 360.97 Mn
Jun 30, 2023 362.70 Mn
Mar 31, 2023 367.59 Mn
Dec 31, 2022 368.75 Mn
Sep 30, 2022 344.55 Mn
Jun 30, 2022 354.41 Mn
Mar 31, 2022 338.66 Mn
Dec 31, 2021 286.77 Mn
Sep 30, 2021 281.00 Mn
Mar 31, 2021 182.39 Mn